This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content is only relevant to HCPs practising in Great Britain (England, Scotland, Wales). This website is optimised for desktop use, and some features may perform differently on mobile devices.

Adverse event reporting can be found at the bottom of the page.

Sanofi branded clouded background image

Latest Articles

Article23 Oct 2023

ESC/EAS DYSLIPIDAEMIA GUIDELINE INTERACTIVE (2 MINUTES)

We know your time is precious, how long do you have?

Praluent® (alirocumab) Prescribing Information (GB)Praluent® (alirocumab) Prescribing Information (NI)

efectos-alirocumab-perfil-lipidico-hero

Article23 Oct 2023

ODYSSEY OUTCOMES Efficacy Praluent® (alirocumab)

Praluent® (alirocumab) Prescribing Information (GB)Praluent® (alirocumab) Prescribing Information (NI)

Article23 Oct 2023

ODYSSEY OUTCOMES Trial Design Praluent® (alirocumab)

Praluent® (alirocumab) Prescribing Information (GB) Praluent® (alirocumab) Prescribing Information (NI)

Article23 Oct 2023

Benefits of switching to Toujeo (insulin glargine 300 Units/mL) through patient case studies and patient reported outcomes

Toujeo® (insulin glargine 300 units/mL) Prescribing Information

Article23 Oct 2023

Explore Toujeo (insulin glargine 300 Units/mL) data from the pivotal randomised controlled clinical trials

Lantus® (insulin glargine 100 units/mL) Prescribing Information UK Toujeo® (insulin glargine 300 units/mL) Prescribing Information UK

Article23 Oct 2023

T1 Evidence in Children

Toujeo® (insulin glargine 300 units/mL) Prescribing Information Lantus® (insulin glargine 100 units/mL) Prescribing Information

Article23 Oct 2023

Praluent® (alirocumab) mechanism of action

Praluent® (alirocumab) Prescribing Information (GB)Praluent® (alirocumab) Prescribing Information (NI)

Article23 Oct 2023

Dosing options – customise your patient’s treatment with Praluent® (alirocumab)

Praluent® (alirocumab) Prescribing Information (GB)Praluent® (alirocumab) Prescribing Information (NI)

Article23 Oct 2023

Treatment and Specialist Treatment Centres in the UK for Pompe disease

MAT-XU-2305061 (v2.0) Date of preparation: February 2024

Therapeutic Areas
- Dermatology
  - Atopic Dermatitis
- Respiratory
  - Asthma
  - COPD
- Cardiology
  - Dyslipidaemia
  - Thrombosis
- Other Topics
  - Payor
  - General Topics
- Rare Disease
  - Pompe
  - Gaucher
  - Better Care for Rare
  - Fabry
- Oncology
  - Multiple Myeloma
  - Other Oncology Topics
- Vaccines
  - Other Vaccines Topics
  - Influenza
  - Travel
- Diabetes
  - Type 1 Diabetes
  - Type 2 Diabetes
- Transplant
  - Transplant
- Neurology
  - Multiple Sclerosis
Articles
- Rare Disease
  - Better Care for Rare
  - Gaucher
  - Pompe
  - Fabry
- Diabetes
  - Type 2 Diabetes
  - Type 1 Diabetes
- Respiratory
  - COPD
  - Asthma
- Cardiology
  - Dyslipidaemia
  - Thrombosis
- Oncology
  - Multiple Myeloma
  - Other Oncology Topics
- Transplant
  - Transplant
- Other Topics
  - General Topics
- Vaccines
  - Influenza
- Neurology
  - Multiple Sclerosis
- Dermatology
  - Atopic Dermatitis
Resources
- Cardiology
  - Dyslipidaemia
- Other Topics
  - Payor
- Rare Disease
  - Pompe
  - Gaucher
- Respiratory
  - Asthma
- Oncology
  - Multiple Myeloma
- Dermatology
  - Atopic Dermatitis
- Vaccines
  - Other Vaccines Topics
  - Influenza
  - Travel
- Diabetes
  - Type 1 Diabetes
Tools
- Dermatology
  - Atopic Dermatitis
- Respiratory
  - Asthma
Events
- Diabetes
  - Type 2 Diabetes
Education
- Vaccines
  - Other Vaccines Topics
- Diabetes
  - Type 1 Diabetes
  - Type 2 Diabetes
- Cardiology
  - Dyslipidaemia
Products